Results 101 to 110 of about 3,873,787 (338)

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]

open access: yes, 2020
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark   +2 more
core  

The metabolic syndrome adds utility to the prediction of mortality over its components: The Vietnam Experience Study [PDF]

open access: yes, 2009
Background\ud The metabolic syndrome increases mortality risk. However, as “non-affected” individuals may still have up to two risk factors, the utility of using three or more components to identify the syndrome, and its predictive advantage over ...
Anna C. Phillips   +24 more
core   +1 more source

Triglyceride-Glucose Index and Neutrophil-to-Lymphocyte Ratio: A Metabolic-Inflammatory Signature for Mortality Prediction in a Multicenter Retrospective Cohort of 1249 Dialysis Patients with Coronary Artery Disease

open access: yesJournal of Inflammation Research
Yike Li,1,* Peng Li,2,* Qiang Tang,3,* Ting Jiao,4 Yanxiang Gao,5 Shuoyan An,5 Hao Jiang,3 Hui Cheng,6 Zixuan Yang,1 Jiahui Zhou,1 Yuxuan Sun,7 Yining Yang,6 Jingang Zheng1,5 1Department of Cardiology, China-Japan Friendship ...
Li Y   +12 more
doaj  

Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease‐modifying therapies. Methods We conducted a nationwide, registry‐based study in Denmark.
Josefine Windfeld‐Mathiasen   +4 more
wiley   +1 more source

Drug treatment of hypertension: focus on vascular health [PDF]

open access: yes, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C.   +2 more
core   +1 more source

IVIG Resistance in Kawasaki Disease: Clinical and Laboratory Risk Factors and the Potential Role of Administration Timing

open access: yesJournal of Inflammation Research
Yue Peng,1– 3,* Fengchuan Jing,1– 3,* Dong Liu,4 Bin Li,5 Yanxia Xu,6 Zhongyou Tan,7 Ouyang Chen,7 Yanfeng Yang,8 Feifei Si,8 Wenliang Jiang,9 Cong Li,9 Zhenli Cheng,1– 3 Xue Zhou,1– 3 Siqi Feng,1– 3 Ya Su,1– 3 Qijian Yi1– 3 1Department ...
Peng Y   +15 more
doaj  

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang   +16 more
wiley   +1 more source

elPBN neurons regulate rVLM activity through elPBN-rVLM projections during activation of cardiac sympathetic afferent nerves. [PDF]

open access: yes, 2016
The external lateral parabrachial nucleus (elPBN) within the pons and rostral ventrolateral medulla (rVLM) contributes to central processing of excitatory cardiovascular reflexes during stimulation of cardiac sympathetic afferent nerves (CSAN).
Fu, Liang-Wu   +3 more
core   +1 more source

Bibliometric Analysis of microRNA: A Comprehensive Evaluation of Its Contribution to Acute Coronary Syndromes

open access: yesJournal of Multidisciplinary Healthcare
Yuqian Gao,1,* Tianli Li,2,* Xiaohong Mu,1,* Xiaoxia Ren,1 Jing Wang,1 Jiasai Fan,1 Haiyan Zhu,1,3 Xian Wang1,3 1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2National ...
Gao Y   +7 more
doaj  

Practice Recommendations for Genetic Testing of Ataxias

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Over the past decade, significant advances in genetic testing for ataxia have improved diagnostic accuracy, informed clinical trial eligibility, guided treatment decisions, and enabled cascade testing of at‐risk relatives. While guidance exists for other neurogenetic conditions, there are no standardized guidelines on genetic ...
Sharan R. Srinivasan   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy